Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.58 |
| ▸ | CA2 | P00918 | 9/20 | 0.58 |
| ▸ | CA12 | O43570 | 5/20 | 0.58 |
| ▸ | CA9 | Q16790 | 5/20 | 0.58 |
| ▸ | DRD2 | P14416 | 5/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5140689 | 0.91 | CA1 (0.53) | CA1CA2CA12CA9DRD2 | |
| SCHEMBL487585 | 0.89 | CA1 (0.59) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL14740749 | 0.87 | CA1 (0.57) | CA1CA2CA12CA9DRD2 | |
| SCHEMBL2822013 | 0.85 | CA1 (0.60) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL27138446 | 0.84 | CA1 (0.55) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL23835564 | 0.84 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL29040473 | 0.84 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL29040410 | 0.84 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL4640090 | 0.84 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL16930099 | 0.84 | CA1 (0.61) | CA1CA2CA12CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928225-B2 | Oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2011-04-19 | — | — | US | disclosed |
| US-20100041911-A1 | Process For The Production Of (Alkoxycarbonylamino)alkyl Sulfonates | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | US | disclosed |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| CN-101243093-A | New oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2008-08-13 | — | — | CN | disclosed |
| EP-1896402-A1 | PROCESS FOR THE PRODUCTION OF (ALKOXYCARBONYLAMINO)ALKYL SULFONATES | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006137774-A1 | PROCESS FOR THE PRODUCTION OF (ALKOXYCARBONYLAMINO)ALKYL SULFONATES | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041911-A1 | Process For The Production Of (Alkoxycarbonylamino)alkyl Sulfonates | HMOX2, CYP2S1, HAO2 | CA1 2521/4885CA2 1616/4885CA12 2156/4885 |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | CA1 2711/4885CA2 2142/4885CA12 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.